Thales and Google Cloud Join Forces to Deliver Breakthrough Capability for Enterprises to Control Their Data in the Cloud
7.12.2020 14:00:00 EET | Business Wire | Press release
Thales announced a new collaboration with Google Cloud that will accelerate the ability of enterprises to safely migrate sensitive data between public cloud, hybrid and private IT infrastructures. Together, the two companies will offer new capabilities that enable security teams to own and control their encryption keys while helping to fulfill heightened regulatory requirements amidst today’s highly-distributed workforce. Building on a multi-year history of innovation around a variety of cloud security initiatives, Thales and Google Cloud will now empower customers to leverage the full potential of Google Cloud technology for sensitive workloads while gaining the external key management needed to control and secure data across hybrid cloud IT environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201207005373/en/
©Thales
Securing the New IT Frontier: Hybrid Cloud
This collaboration marks a significant moment for organisations to finally seize full control of their data and encryption keys, especially as they pursue hybrid, multi-cloud strategies. Addressing both private and public cloud environments, Thales and Google Cloud will provide a turnkey solution that manages, brokers and stores encryption keys completely controlled by the customer, effectively enabling companies to move data assets to the cloud with confidence. As uncovered in the Thales 2020 Data Threat Report-Global Edition, this is increasingly becoming more critical as greater than half of the world’s corporate data – of which 48% is sensitive – is stored in the cloud.
“New capabilities are critical to cloud migration and security, especially with such accelerated growth in this area,” said Sunil Potti, VP and GM of Google Cloud Security. “True to our mission, we've forged this deeper relationship with Thales to further protect our customer’s most sensitive information. Companies of all shapes and sizes are dealing with an extremely fluid and dynamic business environment where even the best lines of defence are constantly being battle tested. Together with Thales, we acknowledge the current set of circumstances and remain vigilant to provide customers with the most advanced solutions that address today’s cybersecurity needs as well as those that are emerging on the horizon.”
This collaboration greatly simplifies the security of moving to multi-cloud, hybrid cloud, and edge-cloud environments – a journey more companies are making today to address the post-pandemic remote world. According to 451 Research, 62% of enterprises today are pursuing a hybrid IT strategy. In addition, by working with Thales to handle application and data security in the cloud, Google Cloud customers can now maintain strong data sovereignty with encryption key visibility and lifecycle management. Customers also can address heightened regulatory requirements stemming from recent data and privacy regulations.
“Our collaboration with Google Cloud truly embodies the technology leadership needed to place the control of data directly into the hands of our customers,” said Sebastien Cano, SVP for Cloud Protection & Licensing at Thales. “Companies no longer need to put their sensitive data in untrusted environments and relinquish control of their coveted encryption keys. It has become abundantly clear that an evolution in data protection is taking place at a global level as security professionals work together to build a shared-responsibility security model between enterprise customers and providers. With this joint innovation effort, we’re supporting organisations as they move to the cloud with confidence.”
Establishing a Foundation of Trust in the Cloud
To help organisations benefit from this enhanced level of control of keys and cloud data, Thales has integrated its CipherTrust Key Broker service with Google Cloud External Key Manager (EKM). The CipherTrust Key Broker for Google Cloud EKM is available on Thales’s Data Protection on Demand platform. By generating encryption keys using CipherTrust Key Broker, organisations can verify the origin and quality of the keys they are providing to the cloud provider, while maintaining the original version of the key outside of the Google Cloud environment. Organisations hold their master keys in a Thales Luna Cloud HSM, which acts as the trust anchor for the CipherTrust Key Broker solution. For more information download the CipherTrust Key Broker solution brief.
Industry insight and views on the latest data security trends can be found on the Thales blog.
Follow Thales on Twitter, LinkedIn, Facebook and YouTube .
About Thales
Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers –businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).
PLEASE VISIT
Thales Group
Market page
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005373/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Market
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
